FMFrédéric Maloisel

Frédéric Maloisel

*This is an algorithmically generated author record based on publicly available information.

Frédéric Maloisel has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • « Regards croisés 2009 » : perceptions croisées des patients atteints de cancer et des professionnels de santé sur leurs relations dans la prise en charge du cancer et de la fatigue

    by F. Maloisel, E. Mitry, L. Zelek, C. Chouaïd, P. Colin, P. Le Calvé

    “Regards croisés 2009” survey was conducted among 300 cancer patients, 250 physicians (oncologists, hematologists, pneumologists, and gastroenterologists) and 109 nurses, in order to evaluate and compare their perceptions of the management of fatigue and chemotherapy-induced anemia. The included patients had a diagnosis of breast, lung or colorectal cancer, or non-myeloid malignant hemopathy, were undergoing ambulatory chemotherapy, and presented or had presented with anemia (Hb < 11 g/dl) during chemotherapy. Fatigue was reported by 77% of the patients, in accordance with the literature. This survey brought new data: patients have expressed great satisfaction in their relations with health professionals, particularly in the management of cancer (notes from 7.5 to 9.1/10), but also, with a little less high notes, in the management of fatigue (notes from 6.6 to 8.4/10). Health professionals’ perceptions were close to those of patients, although they underevaluated the quality of their relations with patients. This shows the positive evolution of cancer patients’ management in France, since the first Cancer patients meeting data published in 1999, which conducted to the first Cancer Plan. General practitioner’s place was also studied according to patients: it seemed to be very important, even if patients appeared more satisfied by informations about cancer and fatigue given by oncologists and others specialists. These data mean that efforts on listening and dialogue with patients have to be enhanced, in accordance with the second Cancer Plan (2009–2013). L’enquête « Regards croisés 2009 » a été réalisée auprès de 300 patients atteints de cancer, de 250 médecins (oncologues, hématologues, pneumologues et gastroentérologues) et de 109 infirmières afin d’évaluer et de comparer leur perception de la prise en charge de la fatigue et de l’anémie chimio-induite. Les patients inclus présentaient une tumeur solide (cancer du sein, du poumon ou colorectal) ou une hémopathie maligne non myéloïde, étaient traités par chimiothérapie et présentaient ou avaient présenté une anémie (hémoglobine [Hb] < 11 g/dl). Trois patients sur quatre (77 %) se plaignaient de fatigue, données qui sont en accord avec celles de la littérature. Des données nouvelles ont été apportées par l’enquête: les patients ont exprimé une grande satisfaction à l’égard de leurs relations avec les professionnels de santé, notamment dans la prise en charge du cancer (notes de 7,5 à 9,1/10), mais aussi avec des notes un peu moins élevées, dans le suivi de leur fatigue (notes de 6,6 à 8,4/10). La perception des professionnels de santé interrogés était en accord avec celle des patients, même s’ils sous-évaluaient la qualité de leur relation avec les patients. Cela montre l’évolution positive de la prise en charge des patients atteints de cancer en France, depuis les états généraux des malades du cancer publiés en 1999 et qui avaient conduit à l’instauration du premier Plan cancer. La place du médecin traitant a aussi été explorée auprès des patients: elle apparaissait essentielle, même si les informations fournies sur la maladie cancéreuse et sur la fatigue semblaient plus satisfaisantes lorsqu’elles provenaient des oncologues et des médecins spécialistes. Ces résultats invitent à poursuivre les efforts d’écoute et de dialogue auprès des patients en accord avec le Plan cancer 2009–2013.


  • Isolated lytic bone lesion as extramedullary disease in chronic myelogenous leukemia: A report of three new cases

    by Frédéric Maloisel, Guillaume Favre, Lahaucine Mahmal, Alina Zamfir, Emmanuel Andrès


  • Life-Threatening Idiosyncratic Drug-Induced Agranulocytosis in Elderly Patients

    by Emmanuel Andrès, Esther Noel, Jean-Emmanuel Kurtz, Nourredine Henoun Loukili, Georges Kaltenbach, Frédéric Maloisel

    Agranulocytosis is a life-threatening disorder in any age, but particularly so in elderly patients who are receiving, on average, a larger number of drugs than younger patients. Drug-induced agranulocytosis still remains a rare event, with an annual incidence rate of approximately 3–12 cases per million population. This disorder frequently occurs as an adverse reaction to drugs, particularly antibacterials, antiplatelet agents, antithyroid drugs, antipsychotics or antiepileptic drugs, and NSAIDs. Although patients experiencing drug-induced agranulocytosis may initially be asymptomatic, the severity of the neutropenia usually translates into the onset of severe sepsis that requires intravenous broad-spectrum antibacterial therapy. In this setting, haematopoietic growth factors have been shown to shorten the duration of neutropenia. Thus, with appropriate management, the mortality rate of idiosyncratic drug-induced agranulocytosis is now 5–10%. However, given the increased life expectancy and subsequent longer exposure to drugs, as well as the development of new agents, physicians should be aware of this complication and its management.


  • Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

    by F Maloisel, L Benboubker, M Gardembas, B Coiffier, M Divine, C Sebban, M Blanc, J-F Abgrall, P Lederlin, J-L Harousseau, et al.

    With the introduction of new drugs such as alpha-interferon (IFN) and purine analogs, the management of hairy cell leukemia (HCL) patients has changed. However, deoxycoformycin (DCF) produced higher complete remission rates than IFN. The current study was undertaken to provide long-term data on duration of overall survival (OS) and disease-free survival (DFS) and incidence of subsequent malignancies. We retrospectively analyzed the data of patients treated with DCF (4 mg/m2/day, every 2 weeks) from 39 French centers. In 84 of 238 included patients, DCF was the first-line therapy. Pretreatment variables influencing the achievement of complete remission, DFS, and OS were identified by multivariate analysis. Two hundred and thirty-eight patients received a median of nine cycles (range, 1–19 cycles). A complete remission was obtained in 182 of 230 evaluable patients (79%) and a partial response was obtained in 38 patients, for an overall response rate of 95.6%. In the multivariate analysis hemoglobin level less than 100 g/l and leukocytes less than 2 109/l were parameters adversely influencing complete remission achievement. With a median follow-up of 63.5 months (range, 0.39–138.4 months), disease recurrence was observed in 34 of 220 responding patients (15%). The estimated 5-years and 10-years DFS was 88.1% and 68.8%, respectively. Hemoglobin level less than 100 g/l and leukocytes less than 2 109/l were the pre-treatment variables associated with a shorter DFS. The estimated 5-year and 10-year OS were 89.4% and 88.7%, respectively. Hemoglobin level less than 100 g/l, leukocytes less than 2 109/l, and adenopathy were significant factors of reduced survival. Hematologic toxicity was the main side-effect, followed by infection and emesis. During the period of follow-up, 18 patients developed second cancer, but the standardized incidence ratio was 0.95. Pentostatin is a highly effective regimen for hairy cell leukemia that produces durable complete responses. Toxicity of DCF is acceptable. Subsequent malignancies do not appear to be increased with pentostatin treatment.


  • Idiopathic Thrombocytopenic Purpura

    by Emmanuel Andrès, Jacques Zimmer, Esther Noel, Georges Kaltenbach, Argyro Koumarianou, Frédéric Maloisel

    To review the influence of age on the response of patients with idiopathic thrombocytopenic purpura (ITP) to corticosteroids, splenectomy and danazol. We retrospectively reviewed a cohort of 139 consecutively treated patients with ITP diagnosed between 1985 and 1994. In particular, we analysed the therapies used, their response rates, prognostic indicators of response and adverse effects. Furthermore, we compared the efficacy and tolerability of the various therapies between younger and older patients (<60 and ≥60 years old). Corticosteroids were used as first-line treatment in 118 patients with an initial response rate of 83%. Age did not affect the outcome of corticosteroid therapy, but all the patients aged ≥60 years reported adverse effects. A splenectomy was performed in 55 patients with an initial response rate of 87%. Older patients had significantly poorer outcomes from splenectomy with higher postoperative morbidity. Finally, danazol was given in 33 patients with a favourable response in 72% of cases. Compared with younger patients, older patients had a significantly better outcome with danazol. Age may have significant effects on the response to and adverse effects of therapy in ITP, and this should be considered when choosing the treatment modality for the elderly.